BioCentury
ARTICLE | Politics & Policy

House Oversight Committee holding EpiPen hearing

September 14, 2016 7:00 AM UTC

The U.S. House Committee on Oversight and Government Reform scheduled a Sept. 21 hearing to discuss price increases for EpiPen from Mylan N.V. (NASDAQ:MYL). The company's CEO Heather Bresch is scheduled to testify, as is FDA Center for Drug Evaluation and Research (CDER) Deputy Director Doug Throckmorton.

Mylan has faced mounting criticism, including from legislators and Hillary Clinton, for its price increases for EpiPen, an epinephrine auto-injector marketed to treat severe acute allergic reactions. ...